PMID-40988099 — Wen: Pancreatitis + Pancreatic Cancer with GLP-1 RAs (Systematic Review, Endocrinol Diabetes Metab 2025)

[DRAFT — authored 2026-04-20. Citation verified against PubMed 2026-04-20. IMPORTANT: Manifest attribution DIFFERS materially from actual paper — see Orchestrator Notes.]

Citation

Wen J, et al. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2025;8(5):e70113. doi: 10.1002/edm2.70113. PMID: 40988099.

External URL: PubMed

Study Design

Design: Systematic review and meta-analysis of randomised controlled trials
RCTs included: 62
Total patients: 66,232
Mean age: 58.3 years
Mean follow-up: 43.5 weeks
Scope: GLP-1 receptor agonists broadly — includes semaglutide, tirzepatide (dual GIP/GLP-1), liraglutide, dulaglutide, exenatide

Key Findings

Pancreatitis (primary analysis)

Pooled RR: 1.44 (95% CI 1.09-1.89), P=0.009 — statistically significantly increased risk
Stratification by background medication use rendered the association non-significant
Authors frame the effect as "slightly increased risk" that is "likely minimal given numerous excluded studies where both arms reported zero events"

Pancreatic cancer

Sample size and follow-up limited for pancreatic cancer analysis; signal inconclusive

Authors' overall conclusion

"GLP-1 RAs carry a slightly increased risk of pancreatitis" — but the magnitude is likely modest given methodological caveats (zero-event-trial exclusions, heterogeneity by background medication).

Clinical Relevance

Wen 2025 is the largest contemporary systematic review of pancreatitis risk with GLP-1 RA therapy. Key teaching points:

RR 1.44 is statistically significant at the primary-analysis level — not a clean reassurance null. This is a real signal, albeit modest in magnitude.
Background-medication stratification attenuates the signal — suggests confounding by concurrent metformin, insulin, or other agents.
Absolute event rates remain low — pancreatitis is a rare AE in any GLP-1 RA trial (typically <1% per year). A 44% relative risk increase on top of a <1% baseline = still <2% absolute risk.
Clinical practice implication: Maintain standard-of-care pancreatitis monitoring (history of pancreatitis as relative contraindication; discontinue if suspected). The Wen data does NOT support removing pancreatitis warnings; it DOES support continued vigilance.
Contrast with earlier-era alarmism: The pancreatitis concern was raised in exenatide post-marketing reports (2013-era). Contemporary evidence confirms a real-but-modest signal, not a catastrophic one.

Orchestrator Notes — Manifest Discrepancy

The T1 Citation Manifest (Batch 2 item S24) attributed the following to this paper:

"31 RCTs, 40,274 patients, semaglutide + tirzepatide NOT associated with increased acute pancreatitis (pooled OR 0.99, 95% CI 0.67-1.45). Frame as reassurance against early-era pancreatitis concern."

The actual paper reports:

62 RCTs (not 31)
66,232 patients (not 40,274)
RR 1.44 (95% CI 1.09-1.89), P=0.009 (not OR 0.99 … 0.67-1.45)
Signal becomes non-significant after background-medication stratification, but the primary analysis is significantly elevated
Authors' framing: "slightly increased risk" (not a clean null)

Integration decision: This research note reflects the actual paper findings. The Semaglutide and Tirzepatide profile prose integrations will cite the nuanced framing (significant primary signal, stratification attenuation, low absolute rates) rather than the mistaken manifest framing. Orchestrator should review Batch 2 manifest accuracy before integrating this citation into new content in future batches.

Linked Peptides

Related Lessons

Lesson 5.2 — Semaglutide Deep Dive (Pancreatitis subsection)
Lesson 5.3 — Tirzepatide Deep Dive (Pancreatitis subsection)
Lesson 5.8 — Side Effect Management

PMID-40988099 – Wen Pancreatitis Pancreatic Cancer GLP-1 Systematic Review